Browsing Genetics and Epidemiology by author "Eeles, Rosalind"
Now showing items 21-40 of 161
-
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.
Telomeres Mendelian Randomization Collaboration,; Haycock, PC; Burgess, S; Nounu, A; Zheng, J; et al. (AMER MEDICAL ASSOC, 2017-05-01)IMPORTANCE: The causal direction and magnitude of the association between telomere length and incidence of cancer and non-neoplastic diseases is uncertain owing to the susceptibility of observational studies to confounding ... -
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Hamdi, Y; Soucy, P; Kuchenbaeker, KB; Pastinen, T; Droit, A; et al. (SPRINGER, 2017-01-01)PURPOSE: Cis-acting regulatory SNPs resulting in differential allelic expression (DAE) may, in part, explain the underlying phenotypic variation associated with many complex diseases. To investigate whether common variants ... -
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
Patel, VL; Busch, EL; Friebel, TM; Cronin, A; Leslie, G; et al. (AMER ASSOC CANCER RESEARCH, 2020-02-01)Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer ... -
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.
Gusev, A; Shi, H; Kichaev, G; Pomerantz, M; Li, F; et al. (NATURE PUBLISHING GROUP, 2016-04-07)Although genome-wide association studies have identified over 100 risk loci that explain ∼33% of familial risk for prostate cancer (PrCa), their functional effects on risk remain largely unknown. Here we use genotype data ... -
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.
Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; et al. (SPRINGER, 2017-07-01)In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ... -
Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; et al. (AMER MEDICAL ASSOC, 2017-12-01)IMPORTANCE: Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ... -
Blood lipids and prostate cancer: a Mendelian randomization analysis.
Bull, CJ; Bonilla, C; Holly, JMP; Perks, CM; Davies, N; et al. (WILEY, 2016-06-01)Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer ... -
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.
Zuber, V; Bettella, F; Witoelar, A; PRACTICAL Consortium,; CRUK GWAS,; et al. (BIOMED CENTRAL LTD, 2017-03-31)BACKGROUND: Epigenetic information can be used to identify clinically relevant genomic variants single nucleotide polymorphisms (SNPs) of functional importance in cancer development. Super-enhancers are cell-specific DNA ... -
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; et al. (AMER ASSOC CANCER RESEARCH, 2015-01-01)BACKGROUND: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same ... -
CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
Nyberg, T; Brook, MN; Ficorella, L; Lee, A; Dennis, J; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-02-10)PURPOSE: Prostate cancer (PCa) is highly heritable. No validated PCa risk model currently exists. We therefore sought to develop a genetic risk model that can provide personalized predicted PCa risks on the basis of known ... -
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study.
Adams, CD; Richmond, R; Ferreira, DLS; Spiller, W; Tan, V; et al. (AMER ASSOC CANCER RESEARCH, 2019-01-01)BACKGROUND: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise ... -
Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study.
Dimitrakopoulou, VI; Tsilidis, KK; Haycock, PC; Dimou, NL; Al-Dabhani, K; et al. (BMJ PUBLISHING GROUP, 2017-10-31)Objective To determine if circulating concentrations of vitamin D are causally associated with risk of cancer.Design Mendelian randomisation study.Setting Large genetic epidemiology networks (the Genetic Associations and ... -
Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study.
Jiang, X; Dimou, NL; Al-Dabhani, K; Lewis, SJ; Martin, RM; et al. (OXFORD UNIV PRESS, 2019-10-01)BACKGROUND: Observational studies have suggested an association between circulating vitamin D concentrations [25(OH)D] and risk of breast and prostate cancer, which was not supported by a recent Mendelian randomization ... -
Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.
Wang, A; Xu, Y; Yu, Y; Nead, KT; Kim, T; et al. (OXFORD UNIV PRESS, 2023-01-13)Little is known regarding the potential relationship between clonal hematopoiesis (CH) of indeterminate potential (CHIP), which is the expansion of hematopoietic stem cells with somatic mutations, and risk of prostate ... -
Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.
Darst, BF; Sheng, X; Eeles, RA; Kote-Jarai, Z; Conti, DV; et al.Although prostate cancer is known to have a strong genetic basis and is influenced by both common and rare variants, the ability to investigate the combined effect of such genetic risk factors has been limited to date. We ... -
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Ahmed, M; Dorling, L; Kerns, S; Fachal, L; Elliott, R; et al. (NATURE PUBLISHING GROUP, 2016-05-10)BACKGROUND: Numerous germline single-nucleotide polymorphisms increase susceptibility to prostate cancer, some lying near genes involved in cellular radiation response. This study investigated whether prostate cancer ... -
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
Fehringer, G; Kraft, P; Pharoah, PD; Eeles, RA; Chatterjee, N; et al. (AMER ASSOC CANCER RESEARCH, 2016-09-01)Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, ... -
DESNT: A Poor Prognosis Category of Human Prostate Cancer.
Luca, B-A; Brewer, DS; Edwards, DR; Edwards, S; Whitaker, HC; et al. (ELSEVIER, 2018-12-01)BACKGROUND: A critical problem in the clinical management of prostate cancer is that it is highly heterogeneous. Accurate prediction of individual cancer behaviour is therefore not achievable at the time of diagnosis leading ... -
Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk.
deSouza, NM; Morgan, VA; Bancroft, E; Sohaib, SA; Giles, SL; et al. (Elsevier BV, 2014-09-07)BACKGROUND: Diffusion-weighted (DW)-MRI is invaluable in detecting prostate cancer. We determined its sensitivity and specificity and established interobserver agreement for detecting tumour in men with a family history ... -
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; et al. (MASSACHUSETTS MEDICAL SOC, 2015-10-29)BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would ...